BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 26171558)

  • 41. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclic amplification of protein misfolding: application to prion-related disorders and beyond.
    Soto C; Saborio GP; Anderes L
    Trends Neurosci; 2002 Aug; 25(8):390-4. PubMed ID: 12127750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
    Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
    Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altered prion protein glycosylation in the aging mouse brain.
    Goh AX; Li C; Sy MS; Wong BS
    J Neurochem; 2007 Feb; 100(3):841-54. PubMed ID: 17144900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prion's elusive reason for being.
    Aguzzi A; Baumann F; Bremer J
    Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prion channel proteins and their role in vacuolation and neurodegenerative diseases.
    Kourie JI
    Eur Biophys J; 2002 Sep; 31(5):409-16. PubMed ID: 12202918
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked.
    Sandberg MK; Al-Doujaily H; Sharps B; De Oliveira MW; Schmidt C; Richard-Londt A; Lyall S; Linehan JM; Brandner S; Wadsworth JD; Clarke AR; Collinge J
    Nat Commun; 2014 Jul; 5():4347. PubMed ID: 25005024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure.
    Cobb NJ; Sönnichsen FD; McHaourab H; Surewicz WK
    Proc Natl Acad Sci U S A; 2007 Nov; 104(48):18946-51. PubMed ID: 18025469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
    Principe S; Maras B; Schininà ME; Pocchiari M; Cardone F
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prion diseases and their biochemical mechanisms.
    Cobb NJ; Surewicz WK
    Biochemistry; 2009 Mar; 48(12):2574-85. PubMed ID: 19239250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Towards cellular receptors for prions.
    Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
    Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein.
    Piening N; Weber P; Giese A; Kretzschmar H
    Biochem Biophys Res Commun; 2005 Jan; 326(2):339-43. PubMed ID: 15582583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prion proteins: a biological role beyond prion diseases.
    Hu W; Rosenberg RN; Stüve O
    Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prion formation, but not clearance, is supported by protein misfolding cyclic amplification.
    Shikiya RA; Eckland TE; Young AJ; Bartz JC
    Prion; 2014; 8(6):415-20. PubMed ID: 25482601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein misfolding and disease: the case of prion disorders.
    Hetz C; Soto C
    Cell Mol Life Sci; 2003 Jan; 60(1):133-43. PubMed ID: 12613663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular biology and pathology of prion strains in sporadic human prion diseases.
    Gambetti P; Cali I; Notari S; Kong Q; Zou WQ; Surewicz WK
    Acta Neuropathol; 2011 Jan; 121(1):79-90. PubMed ID: 21058033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Quick Method to Evaluate the Effect of the Amino Acid Sequence in the Misfolding Proneness of the Prion Protein.
    Fernández-Borges N; Eraña H; Elezgarai SR; Harrathi C; Venegas V; Castilla J
    Methods Mol Biol; 2017; 1658():205-216. PubMed ID: 28861792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.